Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 12/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20189982 | 0.94 | APLNR (0.88) | APLNRHSD17B10TSHRMAPK1DCTPP1 | |
| SCHEMBL17298109 | 0.85 | APLNR (0.74) | APLNRHSD17B10TSHRMAPK1DCTPP1 | |
| Hydrochloric Acid SCHEMBL31608490 | 0.84 | APLNR (0.73) | APLNRHSD17B10TSHRMAPK1DCTPP1 | |
| Hydrochloric Acid SCHEMBL19095396 | 0.84 | APLNR (0.73) | APLNRHSD17B10TSHRMAPK1DCTPP1 | |
| SCHEMBL20514187 | 0.84 | APLNR (0.72) | APLNRHSD17B10TSHRMAPK1DCTPP1 | |
| SCHEMBL20189701 | 0.82 | APLNR (0.69) | APLNRHSD17B10ALDH1A1HPGD | |
| SCHEMBL20188607 | 0.79 | APLNR (0.65) | APLNR | |
| SCHEMBL20187769 | 0.78 | APLNR (1.00) | APLNRHSD17B10TSHRMAPK1DCTPP1 | |
| SCHEMBL22518538 | 0.77 | APLNR (0.63) | APLNR | |
| SCHEMBL20180784 | 0.77 | APLNR (0.73) | APLNRTSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3541805-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018097945-A1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | APLNR 13/4885HSD17B10 1173/4885TSHR 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.